Gene · 1195
CLK1: CDC like kinase 1
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. CLK1: CDC like kinase 1. Genes, record 1195. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/1195
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P49759 | Dual specificity protein kinase CLK1 | 484 | 38 | Ensembl, GeneID, HGNC |
Source UniProt
Patents36
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 40724 | P49759 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 5690 | P49759 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 5347 | P49759 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 1019 | P49759 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 1019 | P49759 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 5347 | P49759 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 5690 | P49759 | Espacenet |
| JP 2025032204 A | 2025-03-11 | 26474 | P49759 | Espacenet |
| EP 4461818 A2 | 2024-11-13 | 26474 | P49759 | Espacenet |
| JP 2023058610 A | 2023-04-25 | 26474 | P49759 | Espacenet |
1 to 10 of 36
See all 36 patentsDrugs0
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
None in this release.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,222
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | CLK1 papers | Newest fiscal year |
|---|---|---|---|
| P40OD010440 | Caenorhabditis Genetics Center | 7 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 6 | 2025 |
| R01HL128239 | Genetic and molecular basis for SRSF2 mutations in myelodysplasia | 6 | 2025 |
| P30CA014051 | Cancer Center Support (Core) Grant | 4 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 4 | 2025 |
| P30DK020541 | NYR-Diabetes Research Center (NYR-DRC) | 4 | 2025 |
| P01CA013106 | Targeting Transcription and Splicing in Cancer | 3 | 2025 |
| P30CA015704 | Cancer Center Support Grant | 3 | 2025 |
| P30CA034196 | Cancer Center Support (CORE) Grant | 3 | 2025 |
| P30DK020593 | Vanderbilt Diabetes Research Center | 3 | 2025 |
1 to 10 of 1,222Source NIH's project files
See all 1,222 nih grantsPapers1,704
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Mesoscale proximity labeling at chromatin leads to identification of small molecule mechanism of action. | Nat Commun | 2026 | 42773171 | PubTator, text mining | PubMed |
| Decoding the off-target potency of DB18: A comparative structural study of CLK1 and TRK kinases. | Comput Biol Chem | 2026 | 42748630 | PubTator, text mining | PubMed |
| A recurrently perturbed 12-gene program marks drug-tolerant persister states across cancer types. | Front Bioinform | 2026 | 42682804 | PubTator, text mining | PubMed |
| Thermo-sensing mechanisms of splicing control by nuclear stress bodies. | Mol Cell | 2026 | 42462707 | PubTator, text mining | PubMed |
| PERK orchestrates an endoplasmic reticulum stress alternative splicing program via CLK1/SRSF1. | Nat Commun | 2026 | 42321166 | PubTator, text mining | PubMed |
| Comprehensive proteogenomic characterization reveals clinically relevant molecular subtypes associated with medulloblastoma progression. | Exp Mol Med | 2026 | 42249086 | PubTator, text mining | PubMed |
| Differential Host Gene Expression Associated with Non-Lactobacillus-dominant Vaginal Microbiomes During Pregnancy. | Res Sq | 2026 | 42245806 | PubTator, text mining | PubMed |
| Identification of novel CLK1 inhibitors by computational fragment-based ligand design, co-crystallization, chemical synthesis and structure activity relationships. | Eur J Med Chem | 2026 | 42176653 | PubTator, text mining | PubMed |
| Phase I Study of Rogocekib in Patients with Advanced, Relapsed, or Refractory Malignant Solid Tumors. | Clin Cancer Res | 2026 | 42148878 | PubTator, text mining | PubMed |
| Phosphoproteomic and kinase networks reveal partial EMT and stress-adaptive growth programs in pediatric Peutz-Jeghers polyps. | Pediatr Res | 2026 | 42082734 | PubTator, text mining | PubMed |
1 to 10 of 1,704
See all 1,704 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/1195
GET https://conductscience.org/api/genes/v1/1195/patents?page=2